Aureus Pharma Releases DDI Predict - an Application for Assessing Risks of Drug-Drug Interactions

Aureus Pharma has announced the release of DDI Predict, a software application to assess the risk of potential drug-drug interactions. This application was developed with the contribution and feedback of a focus group consisting of several major pharmaceutical companies.

Aureus Pharma´ s DDI Predict is designed to automatically calculate the risk of drug-drug interactions associated with Cytochrome P450s via a computer algorithm and to provide in a manner of minutes, a graphical report containing all potential drug-drug interactions between a potential drug candidate and a large panel of other drugs/compounds. This analysis of potential DDI risk is based on the latest FDA risk classification.

The input to the application consists of experimental data for a compound and prior experimental knowledge derived from Aureus´ AurSCOPE ADME knowledge database.

Aureus´ AurSCOPE ADME/DDI knowledge database, contains more than 16,000 compounds, 230,000 biological data points, analyzed from more than 9,000 articles and FDA documents. AurSCOPE ADME/DDI is already in use in major pharmaceutical companies.

"We are pleased to add DDI Predict to Aureus´ product portfolio, and enhance our value proposition in the ADME/Toxicity area" commented Jason Theodosiou, CEO of Aureus Pharma. "Assessing the risk of drug to drug interactions via Aureus DDI Predict will help our customers to optimize their decision process and lead to both cost and time savings during drug discovery and development."